Loading...
Printed on 7/19/2026
For informational purposes only. This is not medical advice.
The NAFLD Fibrosis Score (NFS) is a non-invasive model for advanced fibrosis risk in metabolic dysfunction-associated steatotic liver disease pathways. It helps separate lower-risk patients from those needing specialist evaluation.
Formula: NFS = -1.675 + 0.037 x age + 0.094 x BMI + 1.13 x (IFG/diabetes) + 0.99 x AST/ALT ratio - 0.013 x platelets - 0.66 x albumin
Save your results with a free account
Keep a history of calculations, favorite tools, and access your dashboard anytime.
NFS requires six inputs: age (years), BMI (kg/m²), presence of impaired fasting glucose (IFG) or diabetes (yes=1, no=0), AST:ALT ratio (calculated from the liver function panel), platelet count (×10⁹/L), and albumin (g/dL). These six values are all available from a routine outpatient visit with standard bloodwork. Note the IFG/DM binary variable: either diagnosis scores as 1 — if the patient has diabetes, mark yes regardless of glycemic control.
NFS = −1.675 + (0.037 × age) + (0.094 × BMI) + (1.13 × IFG/DM) + (0.99 × AST/ALT ratio) − (0.013 × platelet count) − (0.66 × albumin). Example: a 50-year-old, BMI 31, no diabetes, AST/ALT ratio 0.85, platelets 220, albumin 4.2 → NFS = −1.675 + 1.85 + 2.914 + 0 + 0.842 − 2.860 − 2.772 = −1.701. This falls below −1.455, suggesting low advanced fibrosis risk. The formula requires careful arithmetic — use the calculator to avoid transcription errors.
Three zones guide management: NFS <−1.455 = advanced fibrosis unlikely (NPV ≥93% for F3-F4); reassure patient, continue lifestyle modification, and recheck annually. NFS −1.455 to +0.676 = indeterminate zone (approximately 40–50% of NAFLD patients); refer for second-line testing — FibroScan (VCTE) is preferred. NFS >+0.676 = advanced fibrosis likely (PPV ≥90%); urgent hepatology referral for FibroScan confirmation, HCC surveillance enrollment if cirrhotic, and esophageal variceal screening. In patients >65 years, interpret with caution as NFS is systematically elevated by age.
Primary care physicians and internists
NFS and FIB-4 are the two endorsed first-line non-invasive tests for NAFLD/MASLD fibrosis staging. NFS provides a complementary perspective when FIB-4 is indeterminate or when a second non-invasive estimate helps guide FibroScan referral decisions.
Hepatologists and gastroenterologists
When both NFS and FIB-4 fall in their respective indeterminate zones, FibroScan referral is clearly indicated. When NFS is low but FIB-4 is indeterminate (or vice versa), the clinician can use discordance to calibrate urgency of second-line testing.
All clinicians managing MASLD
Annual NFS recalculation provides a longitudinal fibrosis trajectory. Rising NFS over 2–3 years (even remaining in the same zone) signals accelerating fibrosis risk. Weight loss of 7–10% or more can produce measurable NFS reduction over 12–24 months.
Endocrinologists and obesity medicine physicians
In patients with metabolic syndrome (obesity, hypertension, dyslipidemia, insulin resistance), NFS provides a structured estimate of liver fibrosis risk that goes beyond abnormal transaminases. The IFG/DM component specifically captures the dramatically increased fibrosis risk in diabetic NAFLD patients.
Bariatric surgeons and pre-operative internists
NFS and FIB-4 are recommended for pre-operative liver assessment in bariatric surgery candidates. Advanced fibrosis (NFS >0.676) may warrant liver biopsy at time of surgery or pre-operative hepatology consultation to ensure appropriate intraoperative and post-operative management.
The 2023 AASLD/AGA MASLD pathway recommends FIB-4 as the primary test, but NFS remains a validated alternative. Using both and looking for concordance improves specificity: concordant low scores (NFS <−1.455 AND FIB-4 <1.30) have very high NPV; concordant high scores (NFS >0.676 AND FIB-4 >2.67) have very high PPV. Discordant results should prompt FibroScan.
NFS uses a single binary variable for IFG or diabetes. If the patient has prediabetes (impaired fasting glucose ≥100 mg/dL) OR type 2 diabetes, score as 1. This variable carries a coefficient of 1.13 — a meaningful contribution. Diabetic NAFLD patients have substantially higher fibrosis risk independently of other variables, reflected by this weighting.
Albumin is subtracted in the NFS formula with a large coefficient (−0.66). Low albumin (e.g., 3.0 g/dL vs 4.5 g/dL) substantially lowers the NFS algebraically — but this is counterintuitive. Low albumin reflects poor hepatic synthetic function (advanced disease), which is already captured by other variables. In practice, an albumin <3.5 g/dL in a NAFLD patient is itself a red flag for advanced disease.
Age multiplied by its positive coefficient (0.037) means elderly patients (>65 years) consistently have higher NFS values independent of fibrosis severity. Combined with the age effect in FIB-4, this creates a pattern where older NAFLD patients land in indeterminate zones more often, leading to more FibroScan referrals. Clinical judgment about the pre-test probability of significant fibrosis remains essential in elderly patients.
While NFS has been validated in large cohorts (AUROC ~0.84 for advanced fibrosis), the 2023 AASLD/AGA Multi-Society Clinical Practice Guideline recommends FIB-4 as the primary non-invasive test due to its simplicity (4 vs 6 variables), broader validation, and availability as an automatic EHR calculation in many systems. NFS is endorsed as an alternative, particularly by EASL (2016 guidelines).
When one test is clearly low and the other is indeterminate, some hepatology practices apply a 'two-test concordance' approach before committing to FibroScan referral — reducing unnecessary elastography demand. However, when both tests are indeterminate or one is high, FibroScan should not be delayed.
Body weight reduction of 7–10% (sustainable lifestyle change or GLP-1 agonist therapy) improves hepatic steatosis, inflammation, and fibrosis in MASLD. Serial NFS and FIB-4 measurements at 12-month intervals provide objective fibrosis trajectory tracking — a rising score despite weight loss is a signal that disease is progressing despite intervention.
NFS requires a pre-existing diagnosis (or strong clinical suspicion) of NAFLD/MASLD. It is not a diagnostic tool for identifying NAFLD in the first place — hepatic steatosis diagnosis requires imaging (ultrasound, MRI-PDFF, CAP on FibroScan) or biopsy. NFS then stages fibrosis risk in those with confirmed steatotic liver disease.
NAFLD Fibrosis Score was developed by Angulo et al. (Hepatology 2007) in 733 NAFLD patients across 4 academic centers. NPV for advanced fibrosis ≥93% at lower cutoff; PPV ≥90% at upper cutoff. Validated in multiple independent cohorts; AUROC for advanced fibrosis approximately 0.84. The 2023 AASLD/AGA Multi-Society Clinical Practice Guideline on MASLD (Rinella et al., Gastroenterology 2023) recommends FIB-4 as the primary non-invasive test, with NFS as a validated alternative. Both NFS and FIB-4 are endorsed by the European Association for the Study of the Liver (EASL Clinical Practice Guidelines, J Hepatol 2016).
Lower scores suggest lower probability of advanced fibrosis, while higher scores indicate increased risk and need for further assessment.
Use NFS in fatty liver disease evaluation when full lab and metabolic inputs are available for fibrosis risk triage.
Performance varies by age and metabolic profile, and indeterminate results are common. NFS should be interpreted with complementary fibrosis tests.
For related assessments, see FIB-4, AST/ALT Ratio and BMI Calculator.
Disclaimer: This tool is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about your health.
April 21, 2026 · trust-baseline
Clinical trust metadata enabled for this tool page with structured review/version fields.
Estimate liver fibrosis risk using age, AST, ALT, and platelet count with the FIB-4 index.
OpenGastroenterologyCalculate the AST/ALT ratio as an adjunct liver injury pattern marker in hepatology evaluation.
OpenBody MetricsCalculate your Body Mass Index (BMI) instantly using height and weight. Free, WHO-validated formula with personalized health category insights for adults.
OpenEndocrinologyEstimate insulin resistance using fasting glucose and fasting insulin with the HOMA-IR equation.
Open